Improving the quality of data in clinical trials in cancer COMPACT Steering Committee* Clinical trials are widely used as a means to test the efficacy of treatments in cancer. The main statistical requirements of a successful Phase III clinical trial are described by Peto et al. (1976) as:
(i) that patients are allocated their treatment in such a way as to avoid bias in the treatment comparisonthis requires some form of randomisation; (ii) that the number of patients entered is sufficiently large to give a reasonable chance of detecting a clinically worthwhile difference; and (iii) that the data gathered from the trial have a high level of reliability and completeness. The first two of these requirements have received lengthy discussion in the literature (Pocock, 1983; Buyse et al., 1984; Freedman, 1989) . Thus an international survey of cancer trials conducted on behalf of the Worth Health Organisation (WHO) has shown that, while randomisation is now commonly employed, it is less usual to find adequate numbers of patients in trials (Pocock, 1978) . This was confirmed to be the case in the United Kingdom (Tate et al., 1979) . Realisation of this lack of patient numbers has led to greater efforts to increase trial size, with the formation of national and international cooperative groups such as the United Kingdom Childhood Cancer Study Group (UKCCSG), United Kingdom Coordinating Committee for Cancer Research (UKC-CCR) and the European Organisation for Research and Treatment of Cancer (EORTC), to organise multicentre studies. Commensurate with this effort, there has been a growth in the number and size of Cancer Trials Offices, providing statistical, computing and data management support, to coordinate the conduct of these trials.
Less attention has been paid to the third requirement of data reliability and completeness. Along with the growth in size of clinical trials comes a corresponding increase in the amount of data handling although an established principle, particularly in large studies, is to collect only information germane to the main question under investigation which is often survival.
Nevertheless, in cancer trials follow-up is often prolonged with the consequential accumulation of substantial data per patient. In addition survival time may not constitute the only endpoint of interest. For example, in adjuvant studies where there may be only a small survival benefit for a drug, the longitudinal assessment of toxicity from chemotherapy is particularly important. Therefore, as well as initial details and disease characteristics of each patient, and the treatment given, cancer trials often require the recording of substantial follow-up information including toxicity data and measures of quality of life. The volume of data collected makes quality control a real problem and one that needs careful planning from the outset. These considerations should influence the clarity of the trial protocol, the corresponding data forms and instructions to personnel involved in data collection and recording.
It is clear that conclusions drawn from a clinical trial depend on the quality of the patient data collected, so it is important that the data are accurate and complete. This is often one aspect of any study for which external validation by, for example, a journal referee, is not possible unless the individual patient data are provided in a suitable format. One consequence is that questions on data accuracy and completeness are omitted from published checklists of the statistical content of medical studies (Gardner et al., 1986) . In contrast such checklists ask direct questions about randomisation and the study numbers necessary to provide sufficient statistical power. Answers to these latter questions should be clear and unambiguous from the text and can be verified, at least indirectly, by a reviewer.
A central theme in the development of a successful strategy to maintain data quality is the designation of a person (or team) responsible for the overall co-ordination of data collection, an activity that has become entitled 'data management'. Since effective analysis of cancer trials requires access to a computer based statistical analysis package, data management in a trial extends to maintenance of an accurate computerised database. To achieve this, automated data quality procedures to aid the detection, review and correction of erroneous values are essential (Friedman et al., 1983; Karison, 1981; Kronmal et al., 1978) . The advent of modern technology may now permit direct entry into the trial data bank. Randomisation is already available through EuroCODE (1990) to, for example, EORTC and some Cancer Research Campaign (CRC) and Medical Research Council (MRC) cancer trails. This facility merely re-emphasises the problem of data quality and raises problems of security and confidentiality.
Data from a multicentre clinical trial should be collected on forms specifically designed for the trial. Typically each patient entered has an entry form, a variable number of follow-up forms and possibly some 'special' single forms. As an example, consider the International Collaborative Cancer Group (ICCG) trial of adjuvant 5-Fluorouracil, Adriamycin and Mitomycin C in operable gastric cancer (Coombes et al., 1990) . For this trial the initial clinical data form records demographic details and medical history of the patient, while two 'special' forms record histology and staging of the tumour and date of randomisation and the particular treatment doses allocated. Two additional 'special' forms record dates and details of first distant metastases and death respectively. Thus there is an initial form, four special forms and repeated follow-up forms. The forms are printed in booklets on NCR paper and allow the top copy to be sent to the Trials Office, where they will be processed to form a computerised data base for the study in question. A duplicate copy of the form is kept in the patients' notes.
An important determinant of success in a multicentre trial is the ability to give participating investigators regular information on the progress of a trial so as to maintain their interest. This usually occurs at regular meetings of participants at which interim reports are presented. These reports should include the most recently collected data that have nevertheless undergone checks for errors and inconsistencies. This is particularly important if the trial has an associated data monitoring committee empowered to cease recruitment to a trial prematurely if circumstances warrant it. The ICCG trial requires immediate feedback of untoward toxicity to the clinicians. Other groups may wish the study coordinators alone to be informed immediately of treatment related deaths, perhaps particularly those associated with an event recorded on an earlier visit form for that patient. Both of these requirements demand rapid data entry so that all information received at the Trials Office must be immediately entered on the data base. In this way the latest information on a particular patient is linked to the earlier data available on that patient.
In anticipation of the receipt of the first complete patient form from the clinical trial an appropriate data base has to be prepared. This is now done for many trials conducted on behalf of the MRC, CRC, UKCCSG and UKCCCR, using COMPACT (COMputer PAckage for Cancer Trials) a menu driven data management package designed on behalf of the MRC and CRC specifically for improving the quality of data in cancer clinical trials that involve detailed patient followup.
An important feature of COMPACT is the use of a file recording the problems arising from forms. All data, whether correct, queried or incorrect, are entered on the computer but those data that are queried, or are known to be incorrect during the entry process, are automatically marked as being suspect and details are recorded in the reserved problems file. This avoids the accumulation of data forms which may contain important information in the Trials Office, awaiting replies concerning less critical items from clinical investigators.
The sequence of events in setting up a trial in COMPACT begins with a definition of the types of forms used and the content of each form. This process is performed interactively, and at the same time error checks can be defined. These error checks are primarily of two types. Thus checks are used to detect values outside defined ranges, for example, normal haematological ranges or to verify that patients indeed satisfy the protocol requirements for entry to the trial. In addition checks are able to test for inconsistencies between separate data items both within and across data forms from a particular patient.
A particularly powerful use of the consistency checking procedure is the ability to compare values at successive visits. The facility to make such cross checks is a strong tool for quality control. For example, although a white blood cell count of 4.0 x 109 1-l recorded at a particular visit would be unlikely to violate a range check, if the same patient had had a count of 8.0 x 109 1-l a month previously this would either cast doubt on one of the readings or signal a rapid deterioration in the patient. Thus although both 4.0 and 8.0 x 109 1-1 would pass a range check, the combination would signal a problem, which may or may not be an error, for that patient. Consistency checks can be as complicated as the protocol demands.
Examples of error checks are given in Table I for an adjuvant breast cancer study which requires the patients to be aged between 18 and 70 and have an initial white blood cell count (WBC) of at least 4.0 x 109 1-. There is also a requirement that any patient experiencing weight loss of more than 10% during treatment should be identified.
Thus the first part of It is our view that data entry to a clinical trial is best done, patient form by patient form, by a Data Manager who is conversant with the trial protocol and who is also responsible for reporting on the progress of the trial to the investigators. Thus the data will be entered by someone who knows the study intimately, the individual patients, albeit indirectly, and the data checking facilities themselves will have been designed with their assistance and experience from other trials. This is perhaps one of the most important guarantees of data quality. In some situations batch entry is unavoidable. For example, in very large trials with large numbers of patient forms arriving daily the data are often entered into the computer file by a 'Keypunch Operator' rather than a 'Data Manager'. In these circumstances patient form by patient form checking procedures at data entry may be entirely absent or at least will be less efficient, perhaps resulting in a proportionally larger number of queries being generated. However such data can be entered into COMPACT in batch mode, and the resulting queries addressed by means of the PROBLEMS file.
The increasing awareness of the need for larger collaborative trials for certain tumour types has resulted in cooperative group trials, and they may be organised in such a way that there is more than one Trials Office involved in the randomisation and data management processes. Such collaboration demands a uniform pattern of data checking and data files that are transferable between sites.
For large studies automated quality control is essential and many Trials Offices have developed their 'in-house' methods for this purpose. The computer software for these systems, however, has generally not been transferable to other working environments. This contrasts sharply with the widespread use of standard statistical analysis packages which have been available on a wide range of computers for many years. There are considerable advantages in using a tried and tested data management package rather than writing software for every new trial, which is an expensive and time consuming operation.
Most data management packages that can be purchased have not been designed specifically for clinical trial use. They tend either to be large, expensive and available only on large computers, or rather basic, resulting in the need for considerable extra development. Most are also difficult for inexperienced computer users. Moreover, we are not aware of any with the vital PROBLEMS and longitudinal data facilities or adequate means of dealing with missing data.
COMPACT has been written with cancer trials in mind and certain fundamental aspects of good clinical trial practice are embedded in the package. Thus there are facilities to monitor the incoming data and provide rapid feedback to the trial co-ordinator, enabling corrective action to be taken when problems arise. One can equally well use COMPACT for Phase II trials in cancer, for trials of treatment for other diseases, or for other types of clinical or laboratory studies requiring follow-up. COMPACT has also been successfully used for epidemiological studies and for teaching purposes in courses involving clinicans and medical statisticians.
There are no constraints on the number of patients that can be entered into a study using COMPACT, apart from overall disc capacity on the computer being used. On a micro computer running MS-DOS, where memory is limited, up to eight forms, 300 variables and 20 visits are possible. There is a detailed user manual. COMPACT is currently in use at ten centres in the United Kingdom running in excess of 100 clinical trials, more than half of which are in cancer. A second generation version of COMPACT is under development.
We believe that COMPACT is particularly suitable for use in smaller Trials Offices where adequate computer programmer support cannot be provided to develop an 'in-house' system. COMPACT can be up and running for a new trial in a matter of days, the exact time depending on the experience of the programmer or data manager and the complexity of the trials forms and follow-up schedules. Organisers of new studies should consider COMPACT before they go to the expense of developing their own computer software. It is available at low cost for CRC and MRC supported groups. Information about availability and support for users may be obtained from J.M. Bliss.
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